Asprosin: a novel peptide hormone related to insulin resistance in women with polycystic ovary syndrome

Alan, Murat; Gürlek, Beril; Yılmaz, Alpay; Akşit, Murat; Aslanıpour, Behnaz; Gülhan, İbrahim; Calan, Mehmet; Taner, Cüneyt Eftal

doi:10.1080/09513590.2018.1512967

Cited by 92 publications

(88 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Besides, the study found that plasma asprosin level was an independent risk factor for PCOS through binary logistic regression analysis (17). Similarly, the positive links between asprosin and PCOS have been reported in another study (29). However, recent research reported that the metabolic characteristics of PCOS patients differed significantly from those of diabetes mellitus patients.…”

Section: Asprosin In Pcosmentioning

confidence: 63%

Asprosin: A Novel Player in Metabolic Diseases

Yuan

Zhu

et al. 2020

Front. Endocrinol.

View full text Add to dashboard Cite

Asprosin, a novel glucogenic adipokine, is encoded by two exons (exon 65 and exon 66) of the gene Fibrillin 1 (FBN1) and mainly synthesized and released by white adipose tissue during fasting. Asprosin plays a complex role in the central nervous system (CNS), peripheral tissues, and organs. It is involved in appetite, glucose metabolism, insulin resistance (IR), cell apoptosis, etc. In this review, we will summarize the newly discovered roles of asprosin in metabolic diseases including diabetes, obesity, polycystic ovarian syndrome (PCOS), and cardiovascular disease (CVD), which may contribute to future clinical diagnosis and treatment.

show abstract

Section: Asprosin In Pcosmentioning

confidence: 63%

Asprosin: A Novel Player in Metabolic Diseases

Yuan

Zhu

et al. 2020

Front. Endocrinol.

View full text Add to dashboard Cite

show abstract

“…Besides the relationship between asprosin and type 2 diabetes mellitus, the roles of asprosin in other diseases were also explored. Alan et al 16 found that asprosin was also related to insulin resistance in women with polycystic ovary syndrome. Duerrschmid et al 17 proved that asprosin was a centrally-acting orexigenic hormone.…”

Section: Discussionmentioning

confidence: 99%

Increased serum level and impaired response to glucose fluctuation of asprosin is associated with type 2 diabetes mellitus

Zhang

Jiang

et al. 2019

J of Diabetes Invest

View full text Add to dashboard Cite

Aims/Introduction Asprosin is a novel secreted adipokine that is induced by fasting and promotes hepatic glucose release. In healthy humans, circulating asprosin shows circadian oscillation with an acute drop coinciding with the onset of eating. The present study investigated whether this circadian oscillation still exists in patients with type 2 diabetes mellitus. Materials and Methods We recruited 60 patients with type 2 diabetes mellitus and 60 individuals with normal glucose tolerance (NGT). All participants completed a 75‐g oral glucose tolerance test. Fasting and 2‐h postprandial serum asprosin concentrations were measured by the enzyme‐linked immunosorbent assay method. Partial correlation coefficients were calculated to analyze the relationships between serum asprosin level and parameters of glucose metabolism. Multiple logistic regression analysis was used to determine the association of serum asprosin level with diabetes. Results Both fasting and postprandial asprosin levels were significantly higher in patients with type 2 diabetes mellitus. The postprandial asprosin level was apparently lower than fasting asprosin level in individuals with NGT. The fasting asprosin level closely correlated with type 2 diabetes mellitus after multiple adjustment (odds ratio 2.329, P = 0.023). Asprosin correlated negatively with change in blood glucose (r = −0.502, P < 0.001) and change in C‐peptide (r = −0.467, P < 0.001) in individuals with NGT, but not in type 2 diabetes mellitus patients. Conclusions Serum asprosin level decreased coinciding with the onset of the oral glucose tolerance test in individuals with NGT, whereas this circadian oscillation was disturbed in type 2 diabetes mellitus patients. The impaired response of asprosin to glucose fluctuation in type 2 diabetes mellitus patients might be one of the reasons for the onset of type 2 diabetes mellitus.

show abstract

“…After the discovery of aprosin by Romero et al , it attracted attention in both experimental and human studies. Some studies have identified asprosin as a biomarker in angina pectoris, as being increased in individuals with glucose dysregulation, as a novel peptide hormone in patients with polycystic ovary syndrome, and related to glucose metabolism and lipid and sex hormone profiles in female patients with metabolic related diseases . Additionally, there have been studies that showed both decreasing and increasing levels of asprosin after exercise .…”

Section: Discussionmentioning

confidence: 99%

Increased serum circulating asprosin levels in children with obesity

Silistre¹,

Hatipoğl²

2020

Pediatrics International

View full text Add to dashboard Cite

Background: Childhood obesity is a growing and significant problem worldwide. Asprosin is a novel adipokine that is significantly associated with glucose and insulin production in the liver during fasting. In the present study, we aimed to demonstrate whether there would be differences between obese, overweight, and normal weight children in terms of serum asprosin levels. Methods: Forty-four children with obesity, 54 overweight children, and 60 normal weight children were compared in terms of serum asprosin levels and other anthropometric, biochemical, and hormonal parameters that are associated with being overweight and with obesity. Results: Serum asprosin levels were found to be significantly different between groups: 70.903 AE 17.49 ng/mL, 79.744 AE 29.54 ng/mL, and 106.293 AE 122.69 ng/mL in normal weight, overweight, and obese children respectively. Post-hoc analysis revealed that the asprosin level was significantly higher in obese children compared with normal weight children (P = 0.009). Additionally, asprosin was found to be a predictor of obesity in multiple regression analysis. Conclusion: Our study is the first to demonstrate increased levels of asprosin in obese children compared with normal weight children. Further studies are needed to demonstrate the role of asprosin in the etiology of childhood obesity, as well as other diseases that might be associated with effects of asprosin.

show abstract

Asprosin: a novel peptide hormone related to insulin resistance in women with polycystic ovary syndrome

Cited by 92 publications

References 15 publications

Asprosin: A Novel Player in Metabolic Diseases

Asprosin: A Novel Player in Metabolic Diseases

Increased serum level and impaired response to glucose fluctuation of asprosin is associated with type 2 diabetes mellitus

Increased serum circulating asprosin levels in children with obesity

Contact Info

Product

Resources

About